Coronary Large Conductance Ca\(^{2+}\)-Activated K\(^+\) Channel Dysfunction in Diabetes Mellitus

Tong Lu* and Hon-Chi Lee*

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States

Diabetes mellitus (DM) is an independent risk of macrovascular and microvascular complications, while cardiovascular diseases remain a leading cause of death in both men and women with diabetes. Large conductance Ca\(^{2+}\)-activated K\(^+\) (BK) channels are abundantly expressed in arteries and are the key ionic determinant of vascular tone and organ perfusion. It is well established that the downregulation of vascular BK channel function with reduced BK channel protein expression and altered intrinsic BK channel biophysical properties is associated with diabetic vasculopathy. Recent efforts also showed that diabetes-associated changes in signaling pathways and transcriptional factors contribute to the downregulation of BK channel expression. This manuscript will review our current understandings on the molecular, physiological, and biophysical mechanisms that underlie coronary BK channelopathy in diabetes mellitus.

Keywords: BK channel, diabetes mellitus, coronary arteries, blood vessels, regulation

INTRODUCTION

Diabetes mellitus (DM) has become a global epidemic. The incidence and the prevalence of DM have steadily increased over the past few decades. According to the WHO report in 2021, over 422 million people worldwide have DM with a prevalence of 8.6%, causing 1.6 million deaths annually.\(^1\) Type 1 diabetes mellitus (T1DM) accounts for 5–10% of the total cases of DM and is caused by autoimmune-mediated destruction of pancreatic β-cells, leading to hyperglycemia and insulin dependence (Bluestone et al., 2010; Op De Beeck and Eizirik, 2016). Type 2 diabetes mellitus (T2DM) represents 90–95% of the total cases of DM and is caused by insulin resistance with hyperinsulinemia, hyperglycemia, and hyperlipidemia in most patients (Pandey et al., 2015; Halim and Halim, 2019).

Both T1DM and T2DM are intimately related to micro-vascular and macro-vascular diseases, including ischemic heart disease, cerebrovascular disease, and peripheral vascular disease, resulting in myocardial infarction, stroke, retinopathy, nephropathy, and neuropathy with organ and tissue damages in 70% of diabetic patients (Kurisu et al., 2003; Yeung et al., 2012; Beckman and Creager, 2016; Sorop et al., 2016). The clinical consequences of diabetic vascular complication are devastating. DM is the leading cause of end stage renal disease, new cases of blindness,

\(^1\)https://www.who.int/health-topics/diabetes#tab=tab_1
and non-traumatic lower extremity amputation, imposing global direct health expenditure of $760 in 2019 with a projected $825 billion by 2030 and $845 billion by 2045 (Williams et al., 2020). Hence, it is critically important to understand the mechanisms of vascular dysregulation in DM so that better diagnostic and therapeutic approaches can be developed to treat diabetic vascular complications more effectively.

Ionic mechanisms play a central role in the regulation of vascular reactivity. Vascular large conductance Ca\(^{2+}\)-activated K\(^{+}\) (BK) channels are major determinants of such regulation. BK channels are densely populated in vascular smooth muscle cells (SMCs), particularly in small resistance arteries, and provide tight regulation of vascular tone and tissue perfusion. It is well established that vascular BK channel expression and function are abnormal in DM. Diabetic patients are known to have worse cardiovascular events and outcome, with higher risks of ischemic heart disease and myocardial infarction (Kurisu et al., 2003; Yeung et al., 2012; Sorop et al., 2016). In this review, we will focus on recent findings in the coronary arterial SMCs, highlighting the diabetes-mediated changes in channel expression, function, and intrinsic properties, as well as the molecular mechanisms associated with these changes.

**STRUCTURE AND FUNCTION OF VASCULAR BK CHANNELS**

Cardiac perfusion is regulated by vasoactive agents released by the endothelium from mechanical sensing of luminal shear stress, including endothelium-derived relaxation factors (EDRF) and endothelium-derived hyperpolarizing factors (EDHF), the pharmacologic action of neuroendocrine factors, and the response of coronary arterial SMCs to intralumenal pressure (Goodwill et al., 2017). Functional vascular BK channels are composed of the pore-forming \(\alpha\)-subunits (BK-\(\alpha\)) and the accessory \(\beta\)-subunits (BK-\(\beta\)) and/or \(\gamma\)-subunits (BK-\(\gamma\); Figure 1; Knaus et al., 1994; Yan and Aldrich, 2012). Four BK-\(\alpha\) and four BK-\(\beta\) assemble to form a functional BK channel. The stoichiometry and interaction between BK-\(\alpha\) and BK-\(\gamma\) are currently unclear. BK-\(\alpha\) is expressed ubiquitously on the cell surface and in mitochondrial membranes of excitable and non-excitable cells, while BK-\(\beta\) is distributed in the cell membranes of excitable cells. BK-\(\gamma\) is mainly found in the cell membrane of non-excitable cells (Singh et al., 2013; Li et al., 2016). BK-\(\alpha\) (encoded by the \(\text{KCNMA1}\)) gene contains the structure of six transmembrane domains (S1–S6) of voltage-gated K\(^{+}\) channels in which S1–S4 constitute the voltage-sensing domain (VSD) and the S5-P loop–S6 firm the ion permeation domain, containing the conserved K\(^{+}\) selectivity filter (TVGYG; Ma et al., 2006; Cui et al., 2009). In addition, the BK channel has a unique S0 segment unit in the extracellular N-terminus and a large C-terminal domain (CTD). The CTD has four cytosolic domains (S7–S10) with two regulators of K\(^{+}\) conductance domains (RCK1 and RCK2) that contain two high-affinity Ca\(^{2+}\) binding sites (Wu and Marx, 2010; Yuan et al., 2010). One such site is the Ca\(^{2+}\) bowl (889-QFLDQDDDD-897) in RCK2 with a Ca\(^{2+}\) concentration at half-maximal effect (EC\(_{50}\)) in the 10\(^{-4}\) M range (Xia et al., 2002; Bao et al., 2004). The other site (D367/E535/R514) is located in RCK1 (Figure 1; Zeng et al., 2005; Zhang et al., 2010b). The RCK1s and RCK2s of four BK-\(\alpha\) subunits form an octameric gating ring that connects to the VSD through a rigid linker (Yuan et al., 2010; Tao et al., 2017). Binding to intracellular free Ca\(^{2+}\) and membrane depolarization activate BK channels through allosteric changes in the gating ring.

In addition to Ca\(^{2+}\)– and voltage-dependent activation, BK-\(\alpha\) activity is tightly regulated by its accessory subunits, BK-\(\beta\) and BK-\(\gamma\) (Li and Yan, 2016; Gonzalez-Perez and Lingle, 2019). Four isoforms of \(\beta\) subunits (BK-\(\beta\)-4, encoded by the \(\text{KCNMB1-4}\) genes) and \(\gamma\) subunits (BK-\(\gamma\)-4, encoded by the \(\text{LRRC26, LRRC38, LRRC52, and LRRC55}\) genes) have been cloned in mammalian cells (Li and Yan, 2016; Gonzalez-Perez and Lingle, 2019).

**FIGURE 1** | Schematic illustration of vascular Ca\(^{2+}\)-activated K\(^{+}\) (BK) channel subunits. BK-\(\alpha\), BK channel \(\alpha\)-subunit; BK-\(\beta\), BK channel \(\beta\)-subunit; BK-\(\gamma\), BK channel \(\gamma\)-subunit; S or TM, transmembrane domain segment; VSD, voltage-sensor domain; RCK, regulator of K\(^{+}\) conductance; LRR, leucine-rich repeat; LRRD, leucine-rich repeat domain; LRRCT, leucine-rich repeat C-terminus; LRRNT, leucine-rich repeat N-terminus; COOH, C-terminus; and NH\(_{2}\), N-terminus.
In vascular SMCs, BK-β1 is the predominant vascular isoform. It contains two transmembrane domains (TM1 and TM2) with a relatively large extracellular loop that can reach the inner mouth of the BK-α channel pore and modulates the binding of iberiotoxin (IBTX) and the effects of fatty acids on BK channel activity (Torres et al., 2014). The TM1 is thought to interact with the S2 of an adjacent BK-α subunit and the TM2 with the S0 of another adjacent BK-α subunit (Liu et al., 2010). The presence of the BK-β1 subunit enhances channel sensitivity to Ca\(^{2+}\) activation.

BK-γ1 is also expressed in vascular SMCs (Evanson et al., 2014). BK-γ1 shares the structure of the leucine-rich repeat (LRR) protein superfamily and contains an extracellular N-terminus with six LRRs, a single transmembrane domain, and a short intracellular C-terminus (Figure 1). The effects of BK-γ1 on BK-α regulation can be reproduced by a 40-amino acid peptide containing the transmembrane domain of BK-γ1, suggesting that this is an important structure in the regulation of BK channel physiology (Li et al., 2016). BK-γ1 is known to enhance BK-α sensitivity to Ca\(^{2+}\) and voltage stimuli by magnitudes similar to those of BK-β1, allowing BK channel activation in the physiological range of intracellular free Ca\(^{2+}\) concentrations and membrane potentials of vascular SMCs (Tanaka et al., 1997; Cox and Aldrich, 2000; Yan and Aldrich, 2012). In heterologous expression systems, BK-β and BK-γ subunits can co-exist in the same functional BK channel complex. Their effects on the intrinsic properties of the channel were additive, suggesting that the multiplicity of BK-β/BK-γ combinations would generate a range of BK channels with distinct functional properties according to the specific stoichiometry of the contributing subunits (Gonzalez-Perez et al., 2015). Since nothing is known about the role of BK-γ in the regulation of coronary BK channels in DM, this review will focus on the findings regarding BK-α and BK-β1 pathophysiology in DM.

Intracellular Ca\(^{2+}\) homeostasis in vascular SMCs is regulated by the balance between sarcoplasmic Ca\(^{2+}\) entry (L-type Ca\(^{2+}\) channels and the transient receptor potential channels; TRP, etc.), release of Ca\(^{2+}\) from the endoplasmic reticulum/sarcoplasmic reticulum, uptake of cytoplasmic Ca\(^{2+}\) into intracellular stores, and extrusion through the sarcolemmal Ca\(^{2+}\) pump and Na\(^{+}\)/Ca\(^{2+}\) exchanger (Leopold, 2015). In vascular SMCs, BK channels link Ca\(^{2+}\) homeostasis with cellular excitability and regulate vascular tone through membrane hyperpolarization, providing a negative feedback mechanism on Ca\(^{2+}\) entry. BK channels are colocalized with L-type Ca\(^{2+}\) channels and TRPC/TRPV channels to form BK channel-Ca\(^{2+}\) signaling complexes in the sarcolemna of vascular SMCs, allowing channel regulation in the local cellular milieu (Earley et al., 2005; Kwan et al., 2009; Suzuki et al., 2013; Hashad et al., 2018). Activation of L-type Ca\(^{2+}\) channels and TRP channels in vascular SMCs produces Ca\(^{2+}\) sparklets and triggers Ca\(^{2+}\) release from the SR to generate Ca\(^{2+}\) sparks (Nelson and Quayle, 1995; Takeda et al., 2011). With a single channel conductance of ~300pS, BK channels contribute to 50% of the total K\(^{+}\) currents in coronary arterial SMCs (Wang et al., 2011; Sun et al., 2020). Activation of vascular BK channels by Ca\(^{2+}\) sparks/sparklets in their vicinity gives rise to spontaneous transient outward currents (STOCs), which hyperpolarize the cellular membrane potentials, inactivate L-type Ca\(^{2+}\) channels and TRP channels, reduce intracellular Ca\(^{2+}\) concentrations, and lead to vasorelaxation (Nelson et al., 1995; Ledoux et al., 2006). In addition, BK channels are also expressed in vascular endothelial cells (ECs). Activation of endothelial BK channels may hyperpolarize adjacent SMCs, bestowing EDHF effects (Bryan et al., 2005; Hughes et al., 2010). Nevertheless, activation of BK channels contributes to more than 70% of total vasodilation induced by bradykinin (Miura et al., 1999) and 40% of total vasodilation induced by shear stress in human coronary resistance vessels (Lu et al., 2019).

**CORONARY BK CHANNEL DYSFUNCTION IN DM**

Both T1DM and T2DM are known to be independent risk factors for cardiac diseases, and cardiovascular diseases continue to be a leading cause of mortality in diabetic patients (Dhalla et al., 1985; Stone et al., 1989; Brindisi et al., 2010; Leon and Maddox, 2015). Although, the prevalence of cardiovascular disease in the general population has decreased by 35–40% over recent decades, such a decline has not been observed in patients with DM (Gregg et al., 2007; Beckman and Creager, 2016; Cefalu et al., 2018). Endothelial dysfunction has been recognized as the mechanism that underlies vascular pathology of DM. Subsequent findings confirm that vascular smooth muscle dysfunction is equally important in the pathophysiology of diabetic cardiovascular complications (Creager et al., 2003).

Impaired BK channel-induced vasodilation was first discovered in the cerebral arteries of fructose-rich diet-induced insulin-resistant rats (Dimitropoulou et al., 2002; Erdos et al., 2002). Patch clamp studies provided direct evidence of BK channel dysfunction in freshly isolated coronary arterial SMCs from Zucker diabetic fatty (ZDF) rats, a genetic animal model of T2DM (Lu et al., 2005). Abnormal vascular BK channel function was also found in other diabetic animal models, including streptozotocin (STZ)-induced T1DM rodents, db/db T2DM mice, high fat diet (HFD)-induced obesity/diabetic mice and swine (Dimitropoulou et al., 2002; Pietryga et al., 2005; Burnham et al., 2006; McGahon et al., 2007; Yang et al., 2007; Dong et al., 2008; Lu et al., 2008, 2010, 2012, 2016, 2017a; Borbouse et al., 2009; Navedo et al., 2010; Zhang et al., 2010a; Mori et al., 2011; Nystoriak et al., 2014; Yi et al., 2014). It is worth noting that diabetic vascular BK channel dysfunction is a common finding in most vascular beds, but the results can vary in different species, animal models, and disease status (Mokelke et al., 2003, 2005; Christ et al., 2004; Pietryga et al., 2005; Burnham et al., 2006; Davies et al., 2007; McGahon et al., 2007; Lu et al., 2008; Borbouse et al., 2009; Navedo et al., 2010; Mori et al., 2011; Rueda et al., 2013; Nystoriak et al., 2014; Nieves-Cintron et al., 2017). It has been found that in freshly isolated coronary arterioles from patients with T2DM, BK channel sensitivity to Ca\(^{2+}\) and voltage activation was reduced, indicating that the intrinsic biophysical properties of BK channels were altered in diabetic patients (Figure 2; Lu et al., 2019).
FIGURE 2 | Impaired vascular BK channel function in patients with T2DM. (A) Coronary arterioles of T2DM patients exhibit diminished BK channel Ca\textsuperscript{2+} sensitivity. Left panel: Representative tracings of inside-out single BK channel currents recorded at +60 mV in an excised patch of freshly isolated atrial coronary arteriolar myocytes from non-diabetic (Ctrl) and T2DM patients. With an increase in free Ca\textsuperscript{2+} concentration, BK channel open probability (nPo) was robust in controls but not in T2DM patients. Dashed lines indicate the closed state (c) of channel. Right panel: The nPo plotted against logarithm Ca\textsuperscript{2+} concentrations (nPo-log[Ca\textsuperscript{2+}] curve) was fitted using the Hill equation. There were significant reductions in Ca\textsuperscript{2+}log[EC\textsubscript{50}] and BK channel maximal nPo in T2DM patients (n = 9) compared to those in non-diabetic controls (n = 12). A rightward shift on the normalized nPo-log[Ca\textsuperscript{2+}] curve of T2DM patients. Data are presented as mean ± SEM. The BK channel maximal nPo and log[EC\textsubscript{50}] were significantly reduced in diabetic patients. (B) Impaired BK channel voltage sensitivity in the coronary arterioles of T2DM patients. Left panel: Representative tracings of inside-out single BK channel currents elicited at different testing
This finding supports the observation that the BK channel response to Ca\(^{2+}\) sparks was diminished in human diabetic vessels. The significance of coronary BK channel dysfunction in DM is underscored by the finding that ischemia–reperfusion-mediated myocardial infarction is exacerbated in STZ-induced T1DM mouse hearts and can be reproduced in non-diabetics hearts after exposure to the BK channel specific inhibitor, iberiotoxin (IBTX; Lu et al., 2016). Since IBTX is membrane impermeable and cardiac myocytes do not have BK-a expression on the sarcolemma, this finding provides evidence of the role of coronary vascular BK channels on cardioprotection during ischemia–reperfusion insults, as well as the loss of its protection in DM.

**Altered BK Channel Protein Expression in Diabetic Vessels**

Altered coronary vascular BK channel expression is common in DM (Burnham et al., 2006; McGahon et al., 2007). However, diverse levels of vascular BK channel expression in DM have been observed. In most case, the protein expressions of BK channels are downregulated in coronary arteries (Burnham et al., 2006; Dong et al., 2008; Lu et al., 2008, 2017a; Zhang et al., 2010a; Rueda et al., 2013; Nystoriak et al., 2014; Li et al., 2017), but it was reportedly increased, despite impaired BK channel function in the coronary arteries of Ossabaw miniature swine with metabolic syndrome (Borbouse et al., 2009). Recently, human BK channel expression was examined in coronary arterioles obtained from atrial biopsies of patients who underwent coronary artery bypass grafting surgery. Protein downregulation was found in both BK-α and BK-β1 in patients with T2DM, compared to age-matched non-diabetic subjects (Lu et al., 2019). However, the mRNA levels of BK-β1 were (McGahon et al., 2007) not reduced in the coronary arteries of STZ-induced T1DM rats (Zhang et al., 2010a), db/db T2DM mice (Li et al., 2017) and HFD-induced diabetic mice (Lu et al., 2017a). The varied reports of BK channel expression suggest that a complex assortment of mechanisms exist in the regulation of vascular BK channel expression and function in DM. Reduced BK channel expression leads to impaired Ca\(^{2+}\) sparks/STOCs coupling, albeit the Ca\(^{2+}\) spark amplitudes and intracellular Ca\(^{2+}\) concentrations are known to be elevated in diabetic vascular SMCs.

**Impaired BK Channel Biophysical Properties and Kinetics in Coronary Arterial SMCs in DM**

Ca\(^{2+}\)-activated K\(^+\) channel currents (I) are determined by the number of activated channels (N), open probability (Po), and channel unitary conductance (i), where I = N Po i. BK channel current density is reduced in the coronary arteries of T1DM and T2DM animal models and in humans with DM (Lu et al., 2005, 2008, 2010, 2012, 2016, 2017a, 2019; Pieryga et al., 2005; Burnham et al., 2006; McGahon et al., 2007; Dong et al., 2008; Zhang et al., 2010a; Nystoriak et al., 2014; Yi et al., 2014; Li et al., 2017; Nieves-Cintron et al., 2017; Tang et al., 2017; Zhang et al., 2020). BK channels are activated by intracellular free Ca\(^{2+}\) concentration and by membrane depolarization (Cox et al., 1997; Lu et al., 2008), and these are impaired in DM (Lu et al., 2008, 2019). BK channel sensitivity to voltage- and Ca\(^{2+}\)-mediated activation can be measured by using inside-out patch clamp studies in which the excised cell membrane can be clamped to various voltages and the cytoplasmic surface of the cell membrane directly exposed to bath solutions containing various free Ca\(^{2+}\) concentrations. In freshly isolated coronary arterial SMCs of ZDF rats at 8 months after the development of hyperglycemia, BK channels had a rightward-shifted Ca\(^{2+}\) concentration-dependent curve, with increased EC\(_{50}\) for Ca\(^{2+}\) activation and decreased Ca\(^{2+}\) cooperativity, compared to those of Lean control rats (Lu et al., 2008). Moreover, BK channel activation by membrane depolarization was also abnormal in coronary arterial SMCs of ZDF rats. The channel open probability–voltage (Po-V) relationships were rightward and downward shifted, with the voltage at 50% maximal Po increased by 40 mV. These results indicate that a higher cytoplasmic Ca\(^{2+}\) concentration and a more depolarized membrane potential are required to activate BK channels in DM. Changes in the intrinsic free energy of Ca\(^{2+}\)-binding (ΔΔCa\(^{2+}\)) that contributes to BK channel activation can be estimated based on the shift of Po-V relationship from 0 to 1 μM free Ca\(^{2+}\) in Lean and ZDF rats using the equation: ΔΔCa\(^{2+}\) = −Δ(zeV\(_{\text{ES}}\)), where z is the number of equivalence charge movement, e is the elementary charge, and V\(_{\text{ES}}\) is the voltage at half maximal activation (Shi et al., 2002). There was a 62.3% decrease in the ΔΔCa\(^{2+}\) in ZDF rats, suggesting a less favorable condition for Ca\(^{2+}\) binding to
vascular BK channel Ca\(^{2+}\) sensors in ZDF rats (Lu et al., 2008). Similar results were also observed in BK channels in freshly isolated coronary microvascular SMCs from the atrial appendages of patients with T2DM. Ca\(^{2+}\)- and voltage sensitivity were significantly impaired in diabetic patients, with the maximal BK channel activity to free Ca\(^{2+}\) and voltage activation reduced by 70 and 50%, respectively (Figure 2; Lu et al., 2019). Such dysregulation contributed to a 27.4% attenuation in shear stress-mediated coronary arteriolar vasorelaxation in diabetic patients compared with non-diabetic controls (Lu et al., 2019). In addition, single BK channel current amplitudes were unaltered in DM, indicating that the conductance property of vascular BK channels is normal in DM.

Vascular large conductance Ca\(^{2+}\)-activated K\(^{+}\) channel gating kinetics contain multiple components of open and closed states and dwell-times (McManus and Magleby, 1988, 1991). In coronary arterial SMCs, the open and closed dwell-time histograms of single BK channels were best fitted with three open-time constants: fast (τ\(_O\)), intermediate (τ\(_0\)), and slow (τ\(_S\)), along with four closed-time constants: fast (τ\(_C\)), intermediate (τ\(_c\)), slow (τ\(_s\)), and very slow (τ\(_c\)). DM affects both channel open dwell-times and channel closed dwell-times. The BK channel mean closed-time constant and the individual closed-time constants were significantly prolonged. At the same time, the channel mean open-time constant and individual open-time constants were significantly reduced in DM. These findings were seen in both ZDF rats and in diabetic patients (Lu et al., 2008, 2019). These changes in BK channel gating kinetics suggest that channel openings are abbreviated, and closures prolonged in DM, with reduced channel Po and maximal activation. Hence, diabetes not only affects BK channel expression, but also alters the intrinsic biophysical properties of the channel.

**KCBMA1 and KCNMB1 Variations Associated With Obesity and DM**

Genome-wide association studies (GWASs) are a powerful tool to find genetic variations associated with diseases. Results from a few studies have shown a strong association between KCNMA1 splicing variants and the incidence of obesity or DM. The results from case–control cohorts involving 4,838 obese and 5,827 control subjects suggested that the KCNMA1 rs2116830*G variant was associated with obesity with a p value of 2.82 × 10\(^{-19}\) (Jiao et al., 2011). A recent study reported that a de novo missense variant in KCNMA1 (c.1123G>A) was identified in an adult male patient with a plethora of developmental phenotypes including neonatal DM. This loss-of-function polymorphism (p. G375A) of BK channel is located in the S6 transmembrane domain of BK channel (Liang et al., 2019). In addition, it is well known that BK-α and BK-β1 undergo extensive alternative pre-mRNA splicing and that these splice variants have significant changes in BK channel intrinsic properties and surface expression (Poulisen et al., 2009). However, the pathophysiological roles of BK channel variants in the development of BK channelopathy in DM are largely unexplored and warrant further investigation.

**SIGNALING MOLECULES AND PATHWAYS MEDIATING VASCULAR BK CHANNEL DYSFUNCTION IN DM**

**Effects of Reactive Oxygen Species on Vascular BK Channel Redox Modification**

Increased reactive oxygen species (ROS) production is a hallmark of diabetic pathophysiology, and the role of ROS on vascular dysfunction has been extensively reviewed (Inoguchi et al., 2003; Konior et al., 2014). ROS is represented by a group of highly reactive molecules that include superoxide anion (O\(_2\)\(^{-}\)), peroxide ion (O\(_2\)\(^{2-}\)), hydrogen peroxide (H\(_2\)O\(_2\)), and peroxynitrite (ONOO\(^{-}\)). In vascular SMCs, multiple enzymatic systems such as the NADPH oxidases (NOXs), xanthine oxidase (XO), nitric oxide synthases (NOS), and the mitochondrial electron transport chain are known to produce O\(_2\)\(^{-}\) and H\(_2\)O\(_2\) (Taniyama et al., 2004; Byron et al., 2016). The NOXs, in particular NOX1 and NOX4, are the most important because they are commonly expressed in vascular cells and are the major source of ROS generation in vessels (Clemus and Griendling, 2006; Konior et al., 2014; Burtenshaw et al., 2017). O\(_2\)\(^{-}\) is converted to H\(_2\)O\(_2\) by superoxide dismutases (SODs) or reacts with nitric oxide (NO) to form ONOO\(^{-}\). H\(_2\)O\(_2\) is further reduced to H\(_2\)O by catalase (CAT) and glutathione peroxidase (GPx; Taniyama and Griendling, 2003). Oxidative stress due to ROS production outweighing their scavenging is implicated in vascular dysfunction associated with T1DM and T2DM. It is well documented that elevated glucose increases the production of intracellular advanced glycation end-products (AGEs), stimulates the protein kinase C (PKC)-dependent activation of NOX1 and NOX4 (Inoguchi et al., 2000; Lu et al., 2006; Deluyker et al., 2017), and reduces the activity and bioavailability of antioxidant enzymes, such as SODs, GSH, CAT, and GPx, which results in higher ROS levels in both vascular ECs and SMCs in DM (Szaleczky et al., 1999; Lu et al., 2012; Tiwari et al., 2013).

Reactive oxygen species triggers many signaling pathways and promotes redox-mediated protein posttranslational modification. We found that redox modification is involved in BK channel dysfunction through hyperglycemia. High glucose culture of HEK293 cells stably expressing BK-α resulted in altered BK-α activity and channel kinetics that were mimicked by the effects of exogenously applied H\(_2\)O\(_2\) in BK-α expressing cells cultured in normal glucose (Lu et al., 2006). A 1-week culture with 22 mM glucose markedly downregulated the protein expression of CAT and CuZn-SOD in HEK293 cells, leading to a 3.3-fold increase of H\(_2\)O\(_2\) concentration to the 10\(^{-3}\)M range. Consequently, high glucose culture produced a 50% reduction of BK-α current density, prolonged the channel activation and deactivation time constants (τ\(_a\) and τ\(_o\)), and upward shifted the τ-V curve, indicating that BK-α activation is suppressed in high glucose conditions (Lu et al., 2006). The effects of high glucose on BK-α voltage-dependent activation were mimicked by acute exposure to 2 mM H\(_2\)O\(_2\). Furthermore, the cysteine residue at 911 (C911) in BK-α is particularly vulnerable to H\(_2\)O\(_2\)-mediated regulation (Tang et al., 2001), and a single substitution of C911 by alanine (C911A) eliminated
most of the inhibitory effects of BK-α under high glucose conditions and to exogenously applied H₂O₂ (Lu et al., 2006). In addition, acute exposure to ONOO⁻ (5–100 μM) significantly suppressed BK channel activity in vascular SMCs (Brzezinska et al., 2000; Liu et al., 2002), but did not alter BK-α voltage-dependent activation (Lu et al., 2006), suggesting that the molecular mechanisms underlying BK channel regulation by H₂O₂ and ONOO⁻ are different. Further studies revealed a 3- to 4-fold increase of 3-nitrotyrosine levels on BK-α protein in freshly isolated aortas from STZ-induced T1DM rats compared to non-diabetic controls, suggesting that ONOO⁻-induced modification of BK-α may be mediated through protein tyrosine nitration rather than protein oxidation (Lu et al., 2010). The precise amino acid residue(s) in BK-α modified by ONOO⁻ has not been identified. Nevertheless, an increase of ROS accumulation is the culprit for the development of BK channel dysfunction in DM.

**Angiotensin II Signaling and Vascular BK Channel Regulation**

Angiotensin II (Ang II) is an oligopeptide hormone, exerting its physiological and pathophysiological effects through binding to Ang II type 1 (AT1R) and type 2 (AT2R) receptors and activating their downstream signaling pathways (Dasgupta and Zhang, 2011). In vascular SMCs, where AT1R is predominantly expressed, Ang II causes vasoconstriction and promotes vascular wall remodeling (Ribeiro-Oliveira et al., 2008). In contrast, activation of AT2R produces vasodilatation and impairs vascular remodeling, effects opposite to those of AT1R (Danyel et al., 2013). AT1R is a G-protein-coupled receptor, which is coupled to Gq, Gßγ, Gαi, and β-arrestin (Kawai et al., 2017; Wang et al., 2018). Binding of Ang II to AT1R in vascular SMCs activates Gq which in turn activates the phospholipase C (PLC)-dependent inositol-1,4,5-triphosphate (IP₃)/diacylglycerol (DAG)-mediated Ca²⁺ signaling cascades, causing an increase in protein kinase C (PKC) activity (De Gasparo et al., 2000; Touyz and Schiffrin, 2000). Activation of PKCβ stimulates NOXs with ROS overproduction under hyperglycemic conditions (Inoguchi et al., 2000; Evcimen et al., 2005; Tian et al., 2007). Another study reported that the C-terminus of AT1R phosphorylation at 695 (S695) and 1151 (S1151) in the C-terminus of BK-α inhibits BK channel current density by 50%, and S1151 phosphorylation by PKC also abolishes BK-α activation by protein kinase A (PKA) and protein kinase G (PKG; Zhou et al., 2001, 2010). On the other hand, the activity of tyrosine-protein kinase is regulated by Gαi and β-arrestin upon AT1R stimulation, causing BK channel dysfunction (Ma et al., 2000; Alioua et al., 2002; Fessart et al., 2005; Tian et al., 2007). In addition to redox-mediated modification of BK-α, it has been shown that PKC-induced serine phosphorylation at 695 (S695) and 1151 (S1151) in the C-terminus of BK-α inhibits BK channel current density by 50%, and S1151 phosphorylation by PKC also abolishes BK-α activation by protein kinase A (PKA) and protein kinase G (PKG; Zhou et al., 2001, 2010). On the other hand, the activity of tyrosine-protein kinase is regulated by Gαi and β-arrestin upon AT1R stimulation, causing BK channel dysfunction (Ma et al., 2000; Alioua et al., 2002; Fessart et al., 2005; Tian et al., 2007). Another study reported that the C-terminus of AT1R physically interacts with the C-terminus of BK-α in heterologous expression system, and such protein–protein interaction between AT1R and BK-α directly inhibits BK-α activity, independent of G-protein-mediated processes (Zhang et al., 2014).

However, AT1R expression, Ang II bioavailability, and tissue sensitivity to Ang II are upregulated in diabetic vessels (Arun et al., 2004; Kawai et al., 2017). The pathophysiological importance of Ang II-mediated BK channel regulation in diabetic coronary

![FIGURE 3](https://example.com/figure3.png)  
**FIGURE 3** | Regulation of BK channels by AT1R signaling and caveolae compartmentalization. In DM, AT1R expression, and caveolae formation are upregulated in vascular SMCs. Upon Ang II activation, AT1R translocates to caveolae, where G-proteins, BK-α, NOX-1, and c-Src are colocalized. In caveolae, AT1R interacts with Gαq to activate PKC and NOX-1 through IP₃/DAG signaling pathway, leading to an increase of ROS production. Meanwhile, the Gαi and β-arrestin complex induces c-Src activation. As a result of AT1R activation, BK-α protein oxidation, tyrosine phosphorylation, and tyrosine nitration are enhanced. In addition, AKT phosphorylates FOXO-3α, which in turn suppresses FOXO-3α nuclear translocation and reduces its transcriptional activities. With high glucose, increased ROS production inhibits AKT function, which promotes FOXO-3α nuclear translocation and facilitates Cav-1 expression. Since BK-β1 is not present in the caveolae, an increase in BK-α compartmentalization in caveolae may lead to physical uncoupling between BK-α and BK-β1 in vascular SMCs. The symbols "n," "o," and "p" represent protein nitration, oxidation, and phosphorylation, respectively.
arteries is supported by the evidence that cardiac infarct size induced by experimental ischemia/reperfusion in STZ-induced T1DM mice was twice as large as non-diabetic mice (Lu et al., 2016). The effects of DM on myocardial ischemia/reperfusion injury can be reproduced by infusion of 2 μM Ang II or 0.1 μM membrane impermeable BK channel inhibitor, IBTX, but attenuated by the BK channel activator, NS-1619 (Lu et al., 2016). Similar results were observed in Akita T1DM mice with exacerbated cardiovascular complications and cardiac and vascular dysfunction, from an imbalance of Ang II/AT1R signaling in DM (Patel et al., 2012). Most importantly, the pathological roles of Ang II signaling are supported by clinical outcomes showing that treatment with AT1R blockers and ACE inhibitors reduced cardiovascular complications and cardiovascular death in patients with DM by 25–30% (Niklason et al., 2004; Abuissa et al., 2005; Cheng et al., 2014; Lv et al., 2018).

**Caveolae Compartmentation and Vascular BK Channel Subcellular Distribution**

Caveolae, which are nonclathrin-coated, flask-shaped invaginations of plasma membrane lipid raft subdomains, are characterized by their signature structural protein caveolin, with caveolin-1 (Cav-1) predominantly expressed in the vasculature (Gratton et al., 2004; Krajewska and Maslowska, 2004). Caveolae have emerged as a central platform for signal transduction in many tissues through the interaction between the Cav scaffolding domain and protein partners that contain a Cav-binding motif (ΦxxGxxxΦ or ΦxxxGxxΦ, where Φ is an aromatic amino acid, and x is any amino acid; Okamoto et al., 1998). Many signaling molecules that are associated with BK channel regulation, such as the β-adrenergic receptors (Bucci et al., 2004), AT1R (Ushio-Fukai and Alexander, 2006; Basset et al., 2009), NOX1 (Hilenski et al., 2004; Wolin, 2004), cellular tyrosin protein kinase Src (c-Src; Zundel et al., 2000; Lee et al., 2001), guanylyl cyclase (Linder et al., 2005; Vellecco et al., 2016), PKA (Heijnen et al., 2004; Linder et al., 2005), protein kinase B (PKB or AKT; Seding et al., 2005), PKC (Zeydanli et al., 2011; Ringvold and Khalil, 2017), PKG (Linder et al., 2005), NOS (Cardenica et al., 1996; Vellecco et al., 2016), and prostacyclin (PGI₂) synthase (PGIS; Spisni et al., 2001), are found in the low buoyant density, caveolae-rich membrane fractions of vascular ECs and SMCs. The significance of Cav-1 on vascular physiology is demonstrated by findings in Cav-1 knockout (KO) mice that show constitutively activated eNOS with elevated NO production as well as a failure to maintain a constant vasocontractile tone, resulting in the development of cardiovascular pathologies (Drab et al., 2001; Razani et al., 2001). Overgeneration of NO facilitates the production of ONOO⁻ and contributes to vascular dysfunction with excessive H₂O₂ accumulation (Pacher et al., 2007).

The consensus sequence of the Cav-binding motif is present in BK-α, but not in BK-β1. Indeed, only BK-α but not BK-β1 is detected in the caveolae-rich fractions of SMCs (Lu et al., 2016). Moreover, BK-α is colocalized in the caveolae with other ion channels (Wang et al., 2005; Riddle et al., 2011; Howitt et al., 2012; Lu et al., 2016), especially those associated with Ca²⁺ spark/sparklet generation, such as L-type Ca²⁺ channels (Suzuki et al., 2013; Saeki et al., 2019), T-type Ca²⁺ channels (Hashad et al., 2018), TRPV4 (Goedicke-Fritz et al., 2015; Lu et al., 2017b), TRPC1, TRPC3, and TRPC6 (Bergdahl et al., 2003; Adebiyi et al., 2011; Grayson et al., 2017) in vascular ECs and SMCs. The close proximity of BK channels with Ca²⁺ entry molecules leads to Ca²⁺ spark-coupled STOCs. However, it has been reported that Cav-1 interacts with BK channels and inhibits BK channel activities in coronary ECs (Wang et al., 2005; Riddle et al., 2011). Cholesterol depletion by methyl-β-cyclodextrin and silencing of Cav-1 by small interference RNA enhance BK currents, while exposure to the scaffolding domain peptide of Cav-1 (AP-CAV) inhibits BK currents (Wang et al., 2005; Riddle et al., 2011). Hence, the presence of caveolae may exert an inhibitory effect on BK channel activity.

Increased Cav-1 expression has been found in most diabetic vessels (Hillman et al., 2001; Bucci et al., 2004; Pascariu et al., 2004; Elcioglu et al., 2010; Uyy et al., 2010; Li et al., 2014). Cav-1 expression is directly upregulated by the Forkhead Box O (FOXO) transcription factor (Sandri et al., 2004; Van Den Heuvel et al., 2005). The FOXO-3a phosphorylation levels are significantly reduced in STZ-induced T1DM rat arteries and in cultured human coronary arterial SMCs (Zhang et al., 2010a). This explains the underlying mechanism that leads to Cav-1 upregulation in DM (Figure 3). Furthermore, in STZ-induced T1DM rats, our results in co-immunoprecipitation experiments show that AT1R, c-Src, and BK-α are enriched in the low buoyant density, caveolae-rich membrane fractions of aortas, compared to non-diabetic rats (Lu et al., 2010). Infusion with Ang II (0.05 μg/kg) results in markedly enhanced AT1R protein translocation to the low buoyant density fractions of aortas after 1h (83.4% of total membrane AT1R in STZ-induced T1DM rats vs. 28.5% in controls), suggesting enhanced AT1R translocation into caveolae-rich lipid rafts upon agonist activation in diabetic vessels, consistent with previous report in cultured vascular SMCs (Ishizaka et al., 1998). However, the precise mechanism underlying AT1R translocation is currently unclear. The levels of vascular BK-α protein oxidation, tyrosine phosphorylation, and tyrosine nitration are significantly increased in STZ-induced T1DM rats, likely due to the co-localization of NOS, NOX1 and c-Src in the caveolae. Since BK-α but not BK-β1 is present in caveolae, BK-α translocation into the caveolae of arteries in STZ-induced T1DM mice may promote the physical dissociation of BK-α and BK-β1 (Lu et al., 2016), which may explain the uncoupling of BK-α and BK-β1 in diabetic vessels. A working framework has emerged in caveolae targeting of BK channel regulation, in which caveolae compartmentalize BK-α with AT1R, NOS, NOXs, and c-Src to form BK-α-receptor-enzyme microdomain complexes in vascular SMCs (Figure 3). Such caveolae compartmentation is enhanced in diabetic vessels, which facilitates the redox modification of BK-α. Of note, because BK-β1 does not translocate into caveolae, such subcellular distribution of BK-α and BK-β1 may contribute to BK-α and BK-β1 functional uncoupling, thereby exacerbating BK channelopathy in diabetic vessels (Figure 3). Additionally, caveolae take part in endosomal trafficking and regulating surface expression of many membrane proteins (Elkin et al., 2016). Taking into account the consequences of upregulation...
of caveolae formation in the vascular SMCs in DM, BK-α caveolae translocation may have important pathophysiological implications for vascular BK channel dysfunction in DM.

**Ubiquitin Proteasome System and Vascular BK Channel Protein Degradation**

Protein homeostasis with a balanced regulation between synthesis and degradation is essential for the maintenance of normal cellular function. Cellular proteins are degraded mainly through the lysosomes and the ubiquitin proteasome system (UPS; Ciechanover, 2005). Lysosomal protein degradation occurs through fusion with endocytotic vesicles. This mechanism of protein degradation is non-specific, and all proteins are digested indiscriminately at the same rate. UPS-mediated protein degradation accounts for 80–90% of protein degradation in mammalian cells and it is substrate-specific (Powell, 2006; Schapira et al., 2019). This process is facilitated by three distinct enzymatic steps that involve an ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a ubiquitin ligase (E3). E1 interacts with ubiquitin through an E1-ubiquitin thioester bond in an ATP-dependent manner. It transfers the activated ubiquitin molecule to a cysteine residue on the E2 enzyme to form an E2-ubiquitin thioester-linked intermediate. The E3 ligase facilitates transfer of the ubiquitin moiety to the substrate protein via an amide bond between the carboxy terminus of ubiquitin and a lysine side chain of the substrate protein. The E3 ligase is substrate-specific, allowing repeated positioning of the distal end of ubiquitin molecule for ubiquitin chain assembly with high precision. The poly-ubiquitinated protein is then recognized for enzymatic degradation in the 26S proteasome (Powell, 2006; Schapira et al., 2019). Hence, the E3 reaction is critical for determining the turnover of specific proteins. There are 617 E3 ligases functionally annotated in the human genome (Li et al., 2008). It is known that F-box (FBXO) proteins are a key component of the Skp1-Cullin-F-box (SCF)-type ubiquitin ligase complex (SCF<sub>FBXO</sub>) and serve as sites for enzyme-substrate interaction (Kipreos and Pagano, 2000). FBXO proteins contain several functional domains such as the F-box domain, the LRRs, and the WD40 repeats for protein-protein interaction. Two muscle-specific FBXO proteins, FBXO-9 and FBXO-32 (also known as atrogin-1), have been found to be upregulated in diabetic vessels. They mediate BK-β1 protein ubiquitination in coronary arterial SMCs (Zhang et al., 2010a). The molecular basis of FBXO-32 and BK-β1 interaction was identified using site-directed mutagenesis and co-immunoprecipitation approaches, which showed that the PDZ-binding motif (ETSV) on BK-β1 is critical for FBXO-32-dependent ubiquitination (Zhang et al., 2010a). Deletion of the consensus sequence of the PDZ-binding motif in BK-β1 significantly decreases BK-β1 protein ubiquitination (Figure 4; Zhang et al., 2010a). Activation of FBXO proteins reduces BK-β1 expression, while knockdown of FBXO and proteasomal inhibition enhances BK-β1 levels, suggesting that accelerated UPS-mediated degradation of BK-β1 is an important mechanism of BK channel regulation in DM.

The muscle RING-finger protein 1 (MuRF1) is another E3 ligase involved in UPS-dependent vascular BK-β1 degradation (Yi et al., 2014). Nuclear factor-κB (NF-κB) sites in the MuRF1 promoter are required for transcriptional activation, while FOXO sites are not (Wu et al., 2014). Overexpression of MuRF1 downregulates BK-β1 expression, impairs BK-β1-mediated BK channel activity, and reduces BK channel-induced vasodilation in mouse coronary arteries. We found that the N-terminus of BK-β1 and the coiled-coil region of MuRF1 are necessary for BK-β1 and MuRF1 interaction (Yi et al., 2014). Importantly, the protein expressions of FBXO-9, FBXO-32, and MuRF1 are unregulated in the arteries of STZ-induced T1DM animals and in primary human coronary arterial SMCs cultured with high glucose (Zhang et al., 2010a, 2020; Lu et al., 2012; Yi et al., 2014). Such upregulation of FBXO expression is mediated through the suppression of PI3K/AKT-dependent phosphorylation in FOXO-3α, thereby promoting FOXO-3α nuclear translocation and binding to the consensus sequence [GTAAA(C/T)A] in the promoter of Fhox gene, activating its transcription (Furuyama et al., 2000). However, activation of MuRF1 is due to an increase of NF-κB-mediated Trims3 (encoding MuRF1) transcription (Wu et al., 2014). In DM or hyperglycemia, the activity of AKT is reduced (Okon et al., 2005), while that of NF-κB is augmented (Narayanan et al., 2014), thereby promoting FBXO and MuRF1 expression (Figure 4). Indeed, inhibition of PKCβ activity by ruboxistaurin, NF-κB activity by TPCA-1, and proteasomal activity by MG132 downregulates BK-β1 ubiquitination, preserves BK-β1 expression, and improves BK channel function in coronary arterial SMCs (Zhang et al., 2010a; Lu et al., 2012; Yi et al., 2014).

BK-α protein expression is also regulated by lysosome and UPS degradation (Wang et al., 2013; Liu et al., 2014; Leo et al., 2015; Song et al., 2018). It has been found that the CRL4A and its substrate cereblon (CRBN) complex (CRL4A<sub>CRBN</sub>) serves as the ubiquitin ligase that interacts with the C-terminus of BK-α and induces BK-α protein degradation in neurons (Liu et al., 2014). A recent study reported that both CRBN and BK-α proteins were targeted by SCF<sub>FBXO-7</sub> ubiquitin ligase complex for ubiquitination and proteolysis, controlling BK-α function and regulating the learning and memory processes in the brain (Song et al., 2018). However, the specific E3 ligase(s) responsible for BK-α protein ubiquitination in blood vessels is unknown, and how the BK-α-specific E3s are regulated in DM remains to be determined.

**Effects of Nuclear Factor Erythroid-2-Related Factor 2 Signaling on Vascular BK Channel Expression**

Nuclear factor erythroid-2-related factor 2 (Nrf2) plays a critical role in the maintenance of intracellular redox homeostasis by regulating multiple downstream antioxidant enzymes and phase II detoxifying enzymes, which include NADPH dehydrogenase quinone 1 (NQO1), glutathione-disulphide reductase (GSR), glutathione translocase (GSTA), thioredoxin (TXN), thioredoxin reductase 1 (TXNRD1), heme oxygenase-1 (HO-1), SODs, CAT, and GPx (Gao and Mann, 2009; Chen et al., 2014). In addition, Nrf2 negatively regulates the expression of NOxs (McSweeney et al., 2016). The function of Nrf2 is principally regulated by the kelch-like ECH-association protein 1 (Keap1), which mediates...
Nrf2 ubiquitination and subsequent proteasomal degradation (Canning et al., 2015; Suzuki and Yamamoto, 2015). In the nuclei, Nrf2 binds to the promoters of antioxidant response elements (AREs) and electrophile response elements (EpREs) through interaction with the Nrf2-binding motif [TGA(G/C) xxC]G, where x represents any amino acid (Chorley et al., 2012). Both the KCNMA1 and KCNMB1 genes contain the consensus sequences of Nrf2-binding motifs in their promoter regions. Using promoter luciferase reporter assays, we confirmed that Nrf2 binds to the ARE of the KCNMA1 promoter, but not to that of KCNMB1 promoter. Mutation of the Nrf2-binding motif in the KCNMA1 promoter abolishes the transcription response to Nrf2 (Sun et al., 2020). In addition, adenoviral expression of Nrf2 significantly augmented the mRNA levels of BK-α and BK-β1 in coronary arterial SMCs (Lu et al., 2017a; Sun et al., 2020). These results suggest that Nrf2 facilitates BK-α mRNA expression through activation of KCNMA1 transcription, whereas the stimulatory effect of Nrf2 on BK-β1 mRNA expression is indirect and may be achieved by activating other transcription factor(s) or signaling mechanisms that upregulate KCNMB1 transcription and expression in vascular SMCs.

Nuclear factor erythroid-2-related factor 2 deficiency has been implicated in diabetic complications including those associated with the heart (Tan et al., 2011; Bai et al., 2013), blood vessels (Ungvari et al., 2011; Miao et al., 2012; Li et al., 2017; Lu et al., 2017a), kidneys (Zheng et al., 2011; Cui et al., 2012), and the brain (Pu et al., 2018; Tarantini et al., 2018). The expression of Nrf2 and its downstream genes is slightly increased in the cardiovascular systems of STZ-induced T1DM mice at 2–3 months after the onset of hyperglycemia, but then becomes significantly downregulated at 5–6 months after the development of hyperglycemia (Tan et al., 2011; Miao et al., 2012; Bai et al., 2013), suggesting the burnout of an important redox protective mechanism in the advanced stages of DM. In db/db and HFD-induced diabetic mice 6 months after the development of hyperglycemia, BK channel activity and BK channel-mediated vasodilation in coronary arteries are impaired, accompanied by a remarkable reduction in Nrf2 and its associated antioxidant enzymes (Li et al., 2017; Lu et al., 2017a). Nrf2 KO mice show excessive ROS production, as well as diminished BK channel expression and function in vascular SMCs (Ashino et al., 2013; Sun et al., 2020). Both mRNA and protein expression of BK-α are downregulated, whereas BK-β1 proteins but not mRNA levels are decreased in the arterial SMCs of Nrf2 KO mice, consistent with the notion that Nrf2 regulates BK-α via transcription, and BK-β1 through posttranscriptional mechanisms (Figure 4; Sun et al., 2020). Administration of dimethyl formamide (DMF, an FDA-approved Nrf2 activator) preserves
BK channel protein expression, BK channel activity, and BK channel-mediated vasodilation in the coronary arteries of db/db and HFD-induced diabetic mice (Li et al., 2017; Lu et al., 2017a). Currently, NrF2 activators such as DMF and sulforaphane (SFN) are being used in clinical trials for cardiovascular diseases and metabolic disorder (Yagishita et al., 2020), but it has not been administered for diabetic patients with coronary heart disease (Houghton, 2019). Whether the beneficial effects of NrF2 activators observed in animal studies would translate into better outcomes in diabetic patients with cardiovascular complications needs to be determined.

**Effects of Calcineurin-Nuclear Factor of Activated T Cells Cytoplasmic 3 Isoform Pathway on BK-β1 Transcription**

Nuclear factor of activated T cells cytoplasmic 3 isoform (NFATc3) belongs to the nuclear factor of activated T cells (NFAT) family of transcription factors that were originally discovered in resting T cells and is important in immune response (Rao et al., 1997). NFATc3 is also involved in the development of skeletal muscle and of the cardiovascular systems (Crabtree and Olson, 2002). The activity of NFATc3 is modulated by the Ca²⁺/calmodulin-dependent phosphatase, calcineurin. Elevation of the intracellular Ca²⁺ concentration activates calmodulin and promotes its binding to calcineurin, leading to calcineurin activation. Activated calcineurin dephosphorylates NFATc3, which in turn induces NFATc3 nuclear translocation. Calcineurin binds to the scaffolding protein A-kinase anchoring protein 150 (AKAP150), corresponding to AKAP79 in humans, which also anchors PKA and L-type Ca²⁺ channel to form a dynamic Ca²⁺ signaling complex (Olivia et al., 2007). AKAP79/150 strongly suppresses PKA-mediated L-type Ca²⁺ channel phosphorylation and is required for the activation of NFAT by local Ca²⁺ influx through L-type channels (Olivia et al., 2007).

Nuclear factor of activated T cells share a conserved DNA-binding domain that specifically binds to the DNA core sequence [(A/T)GGAAA] at the promoter region of target genes, activating gene transcription (Rao et al., 1997). Human and mouse KCNMA1 and KCNMB1 contain at least one NFAT-binding motif in their promoters. Inhibition of vascular BK channels by NFATc3 has been reported, while upregulation of NFATc3 expression by Ang II results in decreased BK channel activity in mouse arteries due to the downregulation of BK-β1 mRNA expression (Nieves-Cintron et al., 2007). The effects of NFATc3 on BK channel activity and BK-β1 mRNA expression are abolished by calcineurin inhibitors, FK506 and cyclosporin A, in the presence of Ang II, a finding that has been confirmed in NFATc3 KO mice (Nieves-Cintron et al., 2007). AKAP150 also participates in NFATc3-mediated BK channel downregulation in HFD-induced diabetic mice (Figure 5; Nystoriak et al., 2014). In HFD-induced diabetic mice, the activity of the AKAP150-NFATc3 signaling pathway is upregulated, contributing to impaired BK channel function with reduced BK-β1 expression and increased vascular tone in the mesenteric arteries. However, in AKAP150 KO mice with HFD consumption, the deleterious effects of HFD on BK channels are not observed (Nystoriak et al., 2014). Recently, in vivo administration of a NFATc3 inhibitor (A285222, Abbott Labs) in Akita T1DM mice is found to improve vascular endothelial function, enhance eNOS activity and NO production, reduce endothelin-1 secretion, lower blood pressure, and improve survival (García-Vaz et al., 2020). The beneficial effects of NFATc3 inhibitors on coronary BK channel function in DM warrant further investigation.

**Arachidonic Acid and Its Metabolites on BK Channel Regulation**

Arachidonic acid (AA), a polyunsaturated omega-6 fatty acid, is abundant in normal human diet and in membrane phospholipids. It is an important precursor to a wide range of bioactive mediators and eicosanoids that regulate a multitude of essential functions in the body (Tallima and El Ridi, 2018). AA is metabolized by three major enzyme systems: It is converted by 12-lipoygenase (12-LOX) into leukotrienes and 12-hydroxyeicosatetraenoic acid (12-HETE), by cytochrome P-450 (CYP-450) epoxypxygenase into epiyoxecosatrienoic acids (EETs), and by cyclooxygenases (COX) into prostaglandins, including PG₁ and thromboxane A₂ (TXA₂; Brash, 2001; Vila, 2004). Additionally, AA can be metabolized by CYP-450 omega-hydroxylase to produce 20-hydroxyeicosatetraenoic acid (20-HETE).

Arachidonic acid (Lu et al., 2005; Kur et al., 2014; Martin et al., 2014, 2021) and its metabolites (EETs, PG₁, 12-HETE, and 20-HETE; Li and Campbell, 1997; Yamaki et al., 2001; Zhang et al., 2001; Zink et al., 2001; Lauterbach et al., 2002; Morin et al., 2007) are known to activate vascular BK channels and promote vasodilation through endothelium-dependent
hyperpolarization mechanisms. Direct exposure to 10μM AA robustly increases BK channel activity in inside-out excised patches from human umbilical arterial SMCs, suggesting activation of BK channels directly by AA (Martin et al., 2021). Extracellular application of AA results in BK channel activation and hyperpolarization of resting membrane potentials in vascular SMCs (Kür et al., 2014; Martin et al., 2021). These changes can be blocked by LOX, CYP, and COX inhibitors, suggesting that AA metabolites affect BK channels. The effects of AA on BK channels require the presence of BK-β1 (Sun et al., 2007; Martin et al., 2021). The activation of vascular BK channels by PGI2 is associated with cAMP-dependent, PKA-mediated phosphorylation. EETs and their metabolites dihydroxyeicosatrienoic acids (DHETs) are also potent BK channel activators and vasodilators, including the human coronary microvessels and internal mammary arteries (Quilley et al., 1997; Archer et al., 2003; Feletou and Vanhoutte, 2006; Larsen et al., 2006). Several different mechanisms of EET- and DHET-mediated BK channel activation have been proposed, including direct activation (Wu et al., 2000; Lu et al., 2001), ADP-ribosylation of Gαs (Fukao et al., 2001; Li et al., 2002), and stimulation of PKA-mediated phosphorylation (Dimitropoulou et al., 2007; Imig et al., 2008). However, AA-induced vasodilation of coronary arterioles via BK channel activity is impaired in high glucose conditions and DM (Lu et al., 2005; Zhou et al., 2005, 2006; Yousif and Benter, 2007; Tsai et al., 2011). PGI2 and EET levels are decreased in patients with cardiovascular diseases (Theken et al., 2012; Mokhtar et al., 2013; Schuck et al., 2013) and DM (Lane et al., 1982; Kazama et al., 1987; Migdalis et al., 2001; Duflot et al., 2019). As a result of these findings, AA metabolites and analogues have been developed as potential therapeutic agents for cardiovascular diseases and diabetic vascular complications (Campbell et al., 2017; Wang et al., 2021).

**FUTURE DIRECTIONS IN DIABETIC BK CHANNEL RESEARCH**

Studies of the regulation of BK channel function and expression have greatly advanced our understanding on the role of BK channels in diabetic cardiovascular complications. DM involves a plethora of signaling abnormalities including those pertaining to insulin, ROS generation, Ang II signaling, and Ca2+ regulation. Thus, it is not surprising that DM affects vascular BK channel expression and function in many different ways, including transcription, translation, post-translation, surface trafficking, and channel degradation. Whether surface trafficking dysregulation of BK channel subunits contributes to BK channelopathy of the vascular SMCs in DM is unknown. Moreover, BK channels do not exist as isolated proteins but are assembled in membrane microdomains of vascular ECs and SMCs. Studies of BK channel organization by scaffolding proteins in close proximity with receptors, enzymes, and Ca2+ sources in blood vessels will provide further insights into BK channel physiology and into the molecular mechanisms underlying BK channelopathy in DM. In addition, our knowledge on BK-γ1 in diabetic BK channel dysregulation is very limited. Little is known about the regulation of vascular BK-γ1 expression and function in hyperglycemia and DM. Since the results of BK channel pathology from diabetic animal models are diverse, it is critical to study vascular BK channel biology and dysfunction using human tissues, which serve as the gold standard for diabetic BK channel research.

Ca2+-activated K+ channels are important regulators of vascular physiology and are critical determinants coronary circulation and cardioprotection. Preservation of BK channel expression and activities protects vascular function in DM. Hence, a better understanding of BK channelopathy and prevention of BK channel abnormalities in DM may lead to better vascular therapeutics and care for patients with DM.

**AUTHOR CONTRIBUTIONS**

TL and HL wrote the manuscript and critically reviewed the final version of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Institute of Health (RO1 HL-080118 and RO1 HL-074180), American Diabetes Association (ADA-JFA-07-39, ADA 1-12-BS-119, ADA 1-16-IBS-195, and ADA 1-18-IBS-210), and the Mayo Clinic.

**REFERENCES**

Abuissa, H., Jones, P. G., Marso, S. P., and O’Keefe, J. H. (2005). Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. *J. Am. Coll. Cardiol.* 46, 821–826. doi: 10.1016/j.jacc.2005.05.051

Adebiyi, A., Narayanan, D., and Jaggar, J. H. (2011). Caveolin-1 assembles type 2 inositol 1,4,5-trisphosphate receptors and canonical transient receptor potential 3 channels into a functional signaling complex in arterial smooth muscle cells. *J. Biol. Chem.* 286, 4341–4348. doi: 10.1074/jbc.M110.179747

Aloua, A., Mahajan, A., Nishimaru, K., Zarei, M. M., and Stefani, E. (2002). Coupling of c-Src to long conductance voltage- and Ca2+-activated K+ channels as a new mechanism of agonist-induced vasoconstriction. *Proc. Natl. Acad. Sci. U. S. A.* 99, 14560–14565. doi: 10.1073/pnas.222348099

Archer, S. L., Gragasin, F. S., Wu, X., Wang, S., and Mcmurtry, S. (2003). Endothelium-derived hyperpolarizing factor in human internal mammary artery is 11,12-epoxyeicosatrienoic acid and causes relaxation by activating smooth muscle BK(Ca) channels. *Circulation* 107, 769–776. doi: 10.1161/01.CIR.0000047278.28407.C2

Arun, K. H., Kaul, C. L., and Ramarao, P. (2004). High glucose concentration augments angiotensin II mediated contraction via AT1 receptors in rat thoracic aorta. *Pharmacol. Res.* 50, 561–568. doi: 10.1016/j.phrs.2004.06.001

Ashino, T., Yamamoto, M., Yoshida, T., and Numazawa, S. (2013). Redox-sensitive transcription factor Nrf2 regulates vascular smooth muscle cell migration and neointimal hyperplasia. *Atherosclerosis. Thromb. Vasc. Biol.* 33, 760–768. doi: 10.1161/ATVBAHA.112.300614

Bai, Y., Cui, W., Xin, Y., Miao, X., and Barati, M. T. (2013). Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation...
and BKCa channels. Circ. Res. 97, 1270–1279. doi: 10.1161/01.RES.0000194321.60300.6d
Elioglou, K. H., Kabasakal, L., Cetinel, S., Conturk, G., and Sezen, S. F. (2010). Changes in caveolin-1 expression and vasoreactivity in the aorta and corpus cavernosum of fructose and streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 642, 113–120. doi: 10.1016/j.ejphar.2010.05.049
Elkin, S. R., Lakoduk, A. M., and Schmid, S. L. (2016). Endocytic pathways and endosomal trafficking: a primer. Wien. Med. Wochenschr. 166, 196–204. doi: 10.1007/s10354-016-0432-7
Erdos, B., Miller, A. W., and Busija, D. W. (2002). Alterations in KATP and BKCa channel function in cerebral arteries of insulin-resistant rats. Am. J. Physiol. Heart Circ. Physiol. 283, H2472–H2477. doi: 10.1152/ajpheart.00516.2002
Evanson, K. W., Bannister, J. P., Leo, M. D., and Jaggar, J. H. (2014). LRC2C is a functional BK channel auxiliary gamma subunit in arterial smooth muscle cells. Circ. Res. 115, 423–431. doi: 10.1161/CIRCRESAHA.115.303407
Evicen, N. D., and King, G. L. (2007). The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 55, 498–510. doi: 10.1016/j.phrs.2007.04.016
Feletou, M., and Vanhoutte, P. M. (2006). Endothelin-derived hyperpolarizing factor: where are we now? Arterioscler. Thromb. Vasc. Biol. 26, 1215–1225. doi: 10.1161/01.ATV.0000112024.13727.2c
Feletou, M., and Vanhoutte, P. M. (2006). Evidence for functional and dynamic microcompartmentation of caveolae in vascular smooth muscle. Arterioscler. Thromb. Vasc. Biol. 26, 115–122. doi: 10.1161/01.ATV.0000194321.60300.6d
Garcia-Cardena, G., Fan, R., Stern, D. F., Liu, J., and Sessa, W. C. (1996). Regulation of BK channels by caveolae in endothelial cells by epoxyeicosatrienoic acid. Mol. Pharmacol. 50, 19–26. doi: 10.1124/mol.59.1.16
Goedicke-Fritz, S., Kaistha, A., Kacik, M., Markert, S., and Hofmeister, A. (2014). AT1 receptor stimulation of BKCa-mediated, endothelium-dependent dilation in rat cremaster muscle artery: association with caveolins and caveaeae. Am. J. Physiol. Heart Circ. Physiol. 302, H2464–H2476. doi: 10.1152/ajpheart.00965.2011
Gonzalez-Perez, V., and Lingle, C. J. (2019). Regulation of BK channels by tyrosine phosphorylation and interacts with caveolin-1. J. Biol. Chem. 271, 27237–27240. doi: 10.1074/jbc.B114.427237
Goodwill, A. G., Dick, G. M., Kiel, A. M., and Tune, J. D. (2017). Regulation of caveolin-1 expression and interacts with caveolin-1. J. Biol. Chem. 272, 113–137. doi: 10.1146/annurev-physiol-022516-034038
Gordon-Salant, S., Aguirre-Ghiso, J. A., Hofmann, F., and Sessa, W. C. (2004). Caveolae-mediated endothelium-dependent dilation restores microvascular endothelial function after initial agonist stimulation. Hypertension 32, 459–466. doi: 10.1161/01.HYP.32.3.3459
Hillman, N., Cox, S., Noble, A. R., and Gallagher, P. J. (2001). Increased protein kinase C dependent activation of NAD(P)H oxidase in diabetic aorta and corpus cavernosum of fructose and streptozotocin-induced diabetic rats. Wien. Med. Wochenschr. 161, 196–204. doi: 10.1007/s10354-016-0432-7
Houghton, C. A. (2019). Sulforaphane is its ‘coming of age’ as a clinically relevant nutraceutical in the prevention and treatment of chronic disease. Oxidative Med. Cell. Longev. 2019:2716870. doi: 10.1155/2019/2716870
Howitt, L., Grayson, T. H., Morris, M. J., Sandow, S. L., and Murphy, T. V. (2012). Dietary obesity increases NO and inhibits BKCa-mediated, endothelium-dependent dilation in rat cremaster muscle artery: association with caveolins and caveaeae. Am. J. Physiol. Heart Circ. Physiol. 302, H2464–H2476. doi: 10.1152/ajpheart.00965.2011
Hughes, J. M., Riddle, M. A., Paffett, M. L., Bosc, L. V. G., and Walker, B. R. (2010). Novel role of endothelial BK Ca channels in altered vasoreactivity following hypoxia. Am. J. Physiol. Heart Circ. Physiol. 299, H1439–H1450. doi: 10.1152/ajpheart.00124.2010
Imig, J. D., Dimitropoulou, C., Reddy, D. S., White, R. E., and Falck, J. R. (2008). Afferent arteriolar dilation to 11, 12-EET analogs involves P2X2 activity and Ca2+-activated K+ channels. Microcirculation 15, 137–150. doi: 10.1080/10739680701456960
Inoguchi, T., Li, P., Umeda, F., Yu, H. Y., and Sakimoto, M. (2000). High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49, 1939–1945. doi: 10.2337/diabetes.49.11.1939
Jiao, H., Arner, P., Hoffstedt, J., Brodin, B., and Dubern, B. (2011). Genome wide association study identifies KCNMA1 contributing to human obesity. BMC Med. Genet. 12:110. doi: 10.1186/1471-2350-12-110
Kawai, T., Forrester, S. J., O’Brien, S., Baggett, A., and Rizzo, V. (2017). AT1 receptor signaling pathways in the cardiovascular system. Pharmacol. Res. 125, 4–13. doi: 10.1016/j.phrs.2017.05.008
Kurisu, S., Inoue, I., Kawagoe, T., Ishihara, M., and Shimatani, Y. (2003). Changes in caveolin-1 expression and vasoreactivity in the aorta and corpus cavernosum of fructose and streptozotocin-induced diabetic rats. Wien. Med. Wochenschr. 163, 196–204. doi: 10.1007/s10354-016-0432-7
Kur, J., Mcgahon, M. K., Fernandez, J. A., Scholfield, C. N., and Mcgeown, J. G. (2004). Role of ion channels and subcellular Ca2+ signaling in signal transduction. Cell. Mol. Biol. Lett. 9, 195–220.
Kurisu, S., Inoue, I., Kawagoe, T., Ishihara, M., and Shimatani, Y. (2003). Role of ion channels and subcellular Ca2+ signaling in signal transduction. Cell. Mol. Biol. Lett. 9, 195–220.
following revascularization for anterior acute myocardial infarction. Intern. Med. 42, 554–559. doi: 10.2169/internalmedicine.42.554
Kwan, H. Y., Shen, B., Ma, X., Kwok, Y. C., and Huang, Y. (2009). TRPC1 associates with BK(Ca) channel to form a signal complex in vascular smooth muscle cells. Circ. J. Gen. Physiol. 147, 337–351. doi:10.1259/circj/10811851
Lane, L. S., Jansen, P. D., Lahav, M., and Rudy, C. (1982). Circulating prostacyclin and thromboxane levels in patients with diabetic retinopathy. Ophthalmology 89, 763–766. doi: 10.1016/S0161-6420(82)74279-6
Larsen, B. T., Miura, H., Hatoum, O. A., Campbell, W. B., and Hammad, B. D. (2006). Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxy hydroxylase inhibition. Am. J. Physiol. Heart Circ. Physiol. 290, H491–H499. doi:10.1152/ajpheart.00927.2005
Lauterbach, B., Barbosa-Sicard, E., Wang, M. H., Honeck, H., and Kargel, E. (2002). Cytochrome P450-dependent eicosapentaenoic acid metabolites are novel BK channel activators. Hypertension 39, 609–613. doi:10.1161/hyto2002.103293
Ledoux, J., Werner, M. E., Brayden, J. E., and Nelson, M. T. (2006). Calcium-activated potassium channels and the regulation of vascular tone. Physiology 21, 69–78. doi:10.1152/physiol.00040.2005
Lee, H., Woodman, S. E., Engelman, J. A., Volonte, D., and Galbiati, F. (2001). Palmitoylation of caveolin-1 at a single site (Cys-156) controls its coupling to the c-Src tyrosine kinase: targeting of dually acylated molecules (GPI-linked, transmembrane, or cytoplasmic) to caveolae effectively uncouples c-Src and caveolin-1 (Tyr-14). J. Biol. Chem. 276, 35150–35158. doi:10.1074/jbc.M104302200
Leo, M. D., Bulley, S., Bannister, J. P., Kuruvilla, K. P., and Narayanan, D. (2015). Angiotensin II stimulates internalization and degradation of arterial myocyte plasma membrane BK channels to induce vasoconstriction. Am. J. Physiol. Cell Physiol. 309, C392–C402. doi:10.1152/ajpcell.00127.2015
Leon, B. M., and Maddox, T. M. (2015). Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J. Diabetes 6, 1246–1258. doi:10.4239/wjd.v6i13.1246
Leopold, J. A. (2015). Vascular calcification: mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc. Med. 25, 267–274. doi:10.1016/j.tcm.2014.10.001
Li, W., Bengston, M. H., Ulbrich, A., Matsuda, A., and Reddy, V. A. (2008). Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 3:e1487. doi:10.1371/journal.pone.0003918
Li, P. L., and Campbell, W. B. (1997). Epoxyeicosatrienoic acids activate K+ channels in coronary smooth muscle through a guanine nucleotide binding protein. Circ. Res. 80, 877–884. doi:10.1161/01.RES.80.6.877
Li, Q., Guan, Y., Yen, K., Zhang, J., and Yan, J. (2016). The single transmembrane segment determines the modulatory function of the BK channel auxiliary gamma and delta subunits. J. Gen. Physiol. 147, 337–351. doi:10.1085/jgp.20151511
Li, Y., Wang, X. L., Sun, X., Chai, Q., and Li, J. (2017). Regulation of vascular large-conductance calcium-activated potassium channels by Nrf2 signalling. Diab. Vasc. Dis. Res. 14, 353–362. doi:10.1177/1794204117703903
Li, X., Xing, W., Wang, Y., Mi, C., and Zhang, Z. (2014). Upregulation of caveolin-1 contributes to aggravated high-salt diet-induced endothelial dysfunction and hypertension in type 1 diabetic rats. Life Sci. 113, 31–39. doi:10.1016/j.lfs.2014.07.027
Li, Q., and Yan, J. (2016). Modulation of BK channel function by auxiliary beta and gamma subunits. Int. Rev. Neurobiol. 128, 51–90. doi:10.1016/bs.irn.2016.03.015
Li, P. L., Zhang, D. X., Ge, Z. D., and Campbell, W. B. (2002). Role of ADP-ribose in 11,12-EET-induced activation of K(Ca) channels in coronary arterial smooth muscle cells. Am. J. Physiol. Heart Circ. Physiol. 282, H1229–H1236. doi:10.1152/ajpheart.00736.2001
Liang, L., Li, X., Moutton, S., Vergano, S. A. S., and Cogne, B. (2019). De novo loss-of-function KCNMA1 variants are associated with a new multiple malformation syndrome and a broad spectrum of developmental and neurological phenotypes. Hum. Mol. Genet. 28, 2937–2951. doi:10.1093/hmg/ddz117
Linder, A. E., Mccluskey, L. P., Cole, K. R. 3rd, Lanning, K. M., and Webb, R. C. (2005). Dynamic association of nitric oxide downstream signaling molecules with endothelial caveolin-1 in rat aorta. J. Pharmacol. Exp. Ther. 314, 9–15. doi:10.1124/jpet.105.083634
receptors and BKCa channels in the Ca(2+)-microdomain of vascular smooth muscle. J. Biol. Chem. 294, 13093–13105. doi: 10.1074/jbc.RA111.008342
Sandri, M., Sandri, C., Gilbert, A., Skurk, C., and Calabria, E. (2004). Foxo transcription factors induce the atrophy-related ubiquitin ligase atrox-1 and function as a receptor for skeletal muscle atrophy. Cell 117, 399–412. doi: 10.1016/S0092-8674(04)00400-3
Schapira, M., Calabrese, M. F., Bullock, A. N., and Crews, C. M. (2019). Targeted protein degradation: expanding the toolbox. Nat. Rev. Drug Discov. 18, 949–963. doi: 10.1038/s41573-019-0047-y
Schuck, R. N., Theken, K. N., Edin, M. L., Cuagey, M., and Bass, A. (2013). Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis 227, 442–448. doi: 10.1016/j.atherosclerosis.2013.01.034
Sedding, D. G., Hermens, J. Seay, U., Eickelberg, O., and Kummer, W. (2005). Caveolin-1 facilitates mechano-sensitive protein kinase B (Akt) signaling in vitro and in vivo. Circ. Res. 96, 635–642. doi: 10.1161/01.RES.0000160610.61306.0f
Shi, J., Krishnamoorthy, G., Yang, Y., Hu, L., and Chaturvedi, N. (2006). Mechanism of magnesium activation of calcium-activated potassium channels. Nature 438, 876–880. doi: 10.1038/nature04991
Singh, H., Lu, R., Bopassa, J. C., Meredith, A. L., and Stefani, E. (2013). Beta-subunit-dependent modulation of hSlo BK current by arachidonic acid. J. Physiol. Heart Circ. Physiol. 311, H1339–H1351. doi: 10.1113/ajpheart.00458.2015
Spisni, E., Griffoni, C., Santi, S., Riccio, M., and Marulli, R. (2001). Colocalization protocystein (PGII) synthase–caveolin-1 in endothelial cells and new roles for PGII in angiogenesis. Exp. Cell Res. 266, 31–43. doi: 10.1016/excr.2001.5198
Stone, P. H., Muller, J. E., Hartwell, T., York, B. J., and Rutherford, J. D. (1989). Mechanism of magnesium activation of calcium-activated potassium channels. Nature 338, 2140, 68–76. doi: 10.1038/nature00941
Sorop, O., Van Den Heuvel, M., Van Ditzhuijzen, N. S., De Beer, V. J., and Heinonen, I. (2016). Coronary microvascular dysfunction after long-term diabetes and hypercholesterolemia. Am. J. Physiol. Heart Circ. Physiol. 311, H1339–H1351. doi: 10.1113/ajpheart.00458.2015
Sun, X., Qian, L. L., Li, Y., Pfiefer, T. M., and Wang, X. L. (2020). Regulation of KCNMA1 transcription by Nrf2 in coronary arterial smooth muscle cells. PLoS Genet. 16, e1007485. doi: 10.1371/journal.pgen.1007485
Sun, X., Zhang, Y., Zhang, G., Zou, L., and Ishii, H. (2004). Beta-arrestin-mediated N-terminal signaling of the angiotensin II type 1 receptor induces beta-arrestin-biased signaling. J. Vasc. Res. 41, 253–274. doi: 10.1152/jappl.00343.2003
Tao, X., Hite, R. K., and Mackinnon, R. (2017). Cryo-EM structure of the open high-conductance Ca(2+)-activated K(+) channel. Nature 541, 46–51. doi: 10.1038/nature20608
Tang, X. D., Daggett, H., Hanner, M., Garcia, M. L., and Mcmanus, O. B. (2001). Oxidative regulation of large conductance calcium-activated potassium channels. J. Gen. Physiol. 117, 253–274. doi: 10.1085/jgp.117.3.253
Tang, X., Qian, L. L., Wang, R. X., Yao, Y., and Dang, S. F. (2017). Regulation of coronary arterial large conductance Ca(2+)-activated K(+) channel protein expression and function by n-3 polyunsaturated fatty acids in diabetic rats. J. Vasc. Res. 54, 329–343. doi: 10.1159/000478970
Taniyama, Y., and Griendling, K. K. (2003). Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 42, 1075–1081. doi: 10.1161/01.HYP.0000100443.09293.4F
